Biological constraints limit the use of rapamycin-inducible FKBP12-Inp54p for depleting PIP$_2$ in dorsal root ganglia neurons

Jaeda C Coutinho-Budd$^1$, Samuel B Snider$^2$, Brendan J Fitzpatrick$^2$, Joseph E Rittiner$^2$ and Mark J Zylka$^{1,2}$*

Abstract

Background: Rapamycin-induced translocation systems can be used to manipulate biological processes with precise temporal control. These systems are based on rapamycin-induced dimerization of FK506 Binding Protein 12 (FKBP12) with the FKBP Rapamycin Binding (FRB) domain of mammalian target of rapamycin (mTOR). Here, we sought to adapt a rapamycin-inducible phosphatidylinositol 4,5-bisphosphate (PIP$_2$)-specific phosphatase (Inp54p) system to deplete PIP$_2$ in nociceptive dorsal root ganglia (DRG) neurons.

Results: We genetically targeted membrane-tethered CFP-FRB$^\text{PLF}$ (a destabilized FRB mutant) to the ubiquitously expressed Rosa26 locus, generating a Rosa26-FRB$^\text{PLF}$ knockin mouse. In a second knockin mouse line, we targeted Venus-FKBP12-Inp54p to the Calcitonin gene-related peptide-alpha (CGRP$\alpha$) locus. We hypothesized that after intercrossing these mice, rapamycin treatment would induce translocation of Venus-FKBP12-Inp54p to the plasma membrane in CGRP$\alpha^+$ DRG neurons. In control experiments with cell lines, rapamycin induced translocation of Venus-FKBP12-Inp54p to the plasma membrane, and subsequent depletion of PIP$_2$, as measured with a PIP$_2$ biosensor. However, rapamycin did not induce translocation of Venus-FKBP12-Inp54p to the plasma membrane in FRB$^\text{PLF}$-expressing DRG neurons (in vitro or in vivo). Moreover, rapamycin treatment did not alter PIP$_2$-dependent thermosensation in vivo. Instead, rapamycin treatment stabilized FRB$^\text{PLF}$ in cultured DRG neurons, suggesting that rapamycin promoted dimerization of FRB$^\text{PLF}$ with endogenous FKBP12.

Conclusions: Taken together, our data indicate that these knockin mice cannot be used to inducibly deplete PIP$_2$ in DRG neurons. Moreover, our data suggest that high levels of endogenous FKBP12 could compete for binding to FRB$^\text{PLF}$, hence limiting the use of rapamycin-inducible systems to cells with low levels of endogenous FKBP12.

Keywords: Phosphatidylinositol 4,5-bisphosphate, PIP$_2$, Rapamycin, Inp54p, FKBP12, Dorsal root ganglia

Background

The immunosuppressant macrolide, rapamycin, induces the dimerization of two naturally occurring protein domains: FK506 Binding Protein 12 (FKBP12) with the FKBP Rapamycin Binding (FRB) domain of mTOR [1]. These domains can be attached to other proteins to temporally and spatially control cell signaling with rapamycin or rapamycin analogs. For example, these domains were used to control cell growth and cell death [2], to translocate proteins to the plasma membrane or nucleus [3-5], and induce G protein-coupled receptor (GPCR) signaling [6].

Additionally, two groups used these domains to directly and selectively deplete the lipid PIP$_2$ in cultured cells [3,4] and show that PIP$_2$ was important for GPCR signaling and ion channel function [7-9]. Both groups used 1) a plasma membrane-anchored FRB domain and 2) a cytosolic PIP$_2$-specific phosphatase (yeast Inositol polyphosphate 5-phosphatase (Inp54p) or mammalian type IV 5-phosphatase) fused to FKBP12. In cell lines transfected with both of these components, rapamycin promoted dimerization of the FRB domain with FKBP12, and induced rapid translocation of the phosphatase to the plasma membrane where it hydrolyzed PIP$_2$. PIP$_2$
hydrolysis was visualized with a biosensor containing the pleckstrin homology (PH) domain of PLCγ1 (PLCγ1-PH) fused to a fluorescent protein [10-12]. This biosensor dissociates from the plasma membrane and enters the cytosol when PIP2 is hydrolyzed to phosphatidylinositol 4-phosphate (PI(4)P) and inorganic phosphate.

To date, this rapamycin-inducible system has been used in cell lines. Given the widespread importance of PIP2 in signaling and ion channel function [8,13,14], we hypothesized that this system, if adapted for use in animals, could also shed light on how alterations in PIP2 affect animal physiology and behavior. For example, PIP2 modulates Transient Receptor Potential (TRP) ion channels involved in heat and cold sensation, including TRPV1 and TRPM8 [15-21]. Moreover, we recently found that thermosensation and nociceptive sensitization could be reduced by indirectly decreasing PIP2 concentration in DRG [22].

Here, we sought to directly and selectively reduce PIP2 concentration in the plasma membrane of nociceptive DRG neurons to study the in vivo importance of PIP2 in regulating thermal sensitivity and nociceptive sensitization. To accomplish this goal, we knocked FKB21-Inp54p fused to a variant of yellow fluorescent protein (Venus) into the CGRPα locus. CGRPα is a marker of peptidergic sensory neurons, a subset of which expresses the thermosensor TRPV1 [23,24]. We generated a second mouse containing a CFP-tagged, membrane-tethered FRB domain knocked into the ubiquitously expressed Rosa26 locus. By crossing both of these mice together, we were able to express both components of the PIP2 phosphatase system in peptidergic, small diameter DRG neurons and evaluate the performance of this system in vitro and in vivo. Unfortunately, we found that Venus-FKB21-Inp54p did not translocate to the plasma membrane in DRG neurons following rapamycin treatment. Furthermore, our data suggests that a biological constraint—namely high levels of endogenous FKB21—limits translocation in murine DRG neurons.

Results

Rapamycin induces translocation of Venus-FKB21-Inp54p from the cytoplasm to plasma membrane in cell lines

Before generating knockin mice, we set out to verify that the rapamycin-inducible phosphatase components functioned in our hands as described [3,4]. For these experiments, we modified the FRB-CFP construct described in Varnai et al. (2006) by replacing the native FRB domain with the destabilized FRBPLF mutant [25,26] to generate FRBPLF-CFP. This mutation confers greater sensitivity to rapamycin analogs, like C20-MaraP, that can be used in vivo [25,26]. This construct also contains the palmitoylation sequence of human growth associated protein 43 (GAP43), a sequence that promotes plasma membrane localization in cell lines and DRG neurons [4,27]. Additionally, we replaced CFP in the yeast Inp54p construct described in Suh et al. (2006) with a yellow fluorescent protein (Venus) to permit simultaneous visualization of Venus-FKB21-Inp54p and FRBPLF-CFP in live or fixed cells. The yeast phosphatase was chosen so that it could be immunologically distinguished from endogenous mouse 5-phosphatases.

When cotransfected into human embryonic kidney 293 (HEK293) cells [28], FRBPLF-CFP localized to the plasma membrane (Figure 1A), Venus-FKB21-Inp54p was localized to the cytoplasm (Figure 1B), and PLCγ1-PH-RFP was bound to the PIP2-rich plasma membrane (Figure 1C, quantified in Figure 1G), as expected. The apparent localization of the Venus-FKB21-Inp54p construct to the plasma membrane at sites of cell-cell contact represents an artifact called “pseudo-localization” [29], and is not actual membrane localization. After treatment with 1 μM rapamycin, there was no change in membrane localization of the FRBPLF domain (Figure 1D), but Venus-FKB21-Inp54p translocated to the plasma membrane (Figure 1E) and hydrolyzed PIP2, as evidenced by displacement of PLCγ1-PH-RFP to the cytoplasm (Figure 1F). Furthermore, rapamycin reduced Gqα-coupled GPCR signaling (using 1 mM carbachol stimulation and calcium imaging as readout; data not shown). Lastly, rapamycin induced translocation of Venus-FKB21-Inp54p to the plasma membrane in additional cell lines, including Rat1 fibroblasts, HeLa cells, and COS7 cells (data not shown).

Targeting FRBPLF-CFP and Venus-FKB21-Inp54p to peptidergic sensory neurons

Small diameter sensory neurons in the DRG can be divided into peptidergic and nonpeptidergic subsets, with CGRP marking peptidergic neurons, and the plant lectin isolecitin B4 (IB4) marking nonpeptidergic neurons [30]. The peptidergic subset responds to stimuli that evoke sensations of pain and itch, expresses the noxious heat receptor TRPV1, and can be genetically targeted by knocking genes into the CGRPα locus [23,24]. Thus, to examine the role of PIP2 in thermal nociception, we knocked Venus-FKB21-Inp54p into the CGRPα locus. Heterozygous and homozygous CGRP-Inp54p mice were viable and fertile. Using immunohistochemistry, 87.9% of all CGRP-immunoreactive DRG neurons contained Venus-FKB21-Inp54p protein (Figure 2A). In contrast, few (3.7%) nonpeptidergic IB4+ neurons contained Venus-FKB21-Inp54p (Figure 2B). These findings were consistent with the limited overlap between CGRP/α1-CGRPα and IB4 [23,24,30,31], and indicate that Venus-FKB21-Inp54p is primarily expressed in peptidergic sensory neurons.

The Rosa26 locus ubiquitously drives expression in all cell types, including DRG neurons [32,33]. Thus, we targeted FRBPLF-CFP to the plasma membrane, using a
strong CMV early enhancer element and chicken beta-actin (CAG) promoter in the Rosa26 locus, to drive higher gene expression than the endogenous Rosa26 promoter alone [34]. Rosa-FRB\textsuperscript{PLF} heterozygous and homozygous mice were viable and fertile. Using immunohistochemistry, we found that FRB\textsuperscript{PLF}-CFP was present on the plasma membrane of approximately 99% of all DRG neurons (Figure 2C). For all conditions, n > 500 neurons were counted from two animals.

**Rapamycin did not induce translocation of Venus-FKBP12-Inp54p from the cytoplasm to the plasma membrane in DRG neurons**

We next crossed Rosa-FRB\textsuperscript{PLF} mice with CGRP-Inp54p mice to generate compound heterozygotes that expressed both components in peptidergic DRG neurons (Figure 3A). Intrathecal (i.t.) injection of rapamycin was previously used to dimerize mTOR-FKBP12 in DRG neurons in vivo [35,36]. In light of this information, we intrathecally injected CGRP-Inp54p\textsuperscript{+/−} (controls) and Rosa-FRB\textsuperscript{PLF}/CGRP-Inp54p compound heterozygous mice with rapamycin (3 injections, spread over 24 h). Animals were perfused shortly after the final rapamycin injection to fix proteins that may have translocated. DRG were then dissected, cryo-sectioned, and mounted for imaging. Translocation of Venus-FKBP12-Inp54p was assessed by quantifying the location of endogenous Venus fluorescence without immunoenhancement, as we were unable to use antibodies to GFP/Venus because they cross-react to CFP, a highly related protein. Venus and CFP were present in our mice as single-copy knockins, making it difficult to see endogenous fluorescence without increasing gain, and explaining why signals were weak. Unfortunately, this rapamycin treatment did not induce translocation of Venus-FKBP12-Inp54p from the cytoplasm to the plasma membrane in controls or in double heterozygous mice.

![Figure 1](http://www.jnrbm.com/content/12/1/13)

**Figure 1** Inp54p translocates to plasma membrane in HEK293 cells, reducing PIP\textsubscript{2} biosensor levels following rapamycin treatment. A-F) HEK293 cells were transfected with plasmids encoding FRB\textsuperscript{PLF}-CFP, Venus-FKBP12-Inp54p and PLC\textsubscript{δ1PH-RFP}, a PIP\textsubscript{2} biosensor. One day later, cells were imaged by live-cell confocal microscopy. Before rapamycin treatment, (A) FRB\textsuperscript{PLF}-CFP, (B) Venus-FKBP12-Inp54p, and (C) PLC\textsubscript{δ1PH-RFP} were properly localized to the (A,C) membrane or (B) cytoplasm. While localization of FRB\textsuperscript{PLF}-CFP remains constant, rapamycin (1 μM) induced rapid (<3 s) translocation of (E) Venus-FKBP12-Inp54p to the plasma membrane and (F) reduced PLC\textsubscript{δ1PH-RFP} levels at the membrane, indicative of PIP\textsubscript{2} hydrolysis. G) Quantification of translocation in HEK293 cells. **P < 0.005 compared to pre-rapamycin condition, n = 20 cells per condition. Scale bar, 10 μm.
Rapamycin treatment did not affect behavior in Rosa-FRB<sup>PLF</sup>/CGRP-Inp54p heterozygous mice in vivo

We recently found that PIP<sub>2</sub> levels in DRG at the time of inflammation endurably affected thermal hypersensitivity, with preemptively reduced PIP<sub>2</sub> levels correlating with an enduring reduction in thermal hypersensitivity [22]. Thus, we hypothesized that complete Freund adjuvant (CFA)-induced thermal hypersensitivity would be blunted in Rosa-FRB<sup>PLF</sup>/CGRP-Inp54p mice if rapamycin caused a significant depletion of PIP<sub>2</sub>. Although we did not observe translocation in rapamycin-injected animals, we hypothesized that behavior might be a more sensitive readout of system performance than translocation. First, we performed control experiments with CGRP-Inp54<sup>+/−</sup> mice to ensure that expression of this phosphatase alone had no effect on behavioral responses. We tested noxious thermal and mechanical sensitivity in wild-type (WT) and CGRP-Inp54p heterozygous littermates before and after inflaming one hindpaw with CFA, to model chronic inflammatory pain. We found that WT and CGRP-Inp54p<sup>+/−</sup> mice showed no significant differences in paw diameter, thermal sensitivity or mechanical sensitivity before or after CFA injection (Figure 4A-C). Thus, expression of Venus-FKBP12-Inp54p in CGRPα-positive neurons did not alter nociceptive behavioral responses.

Next, we tested the effects of preemptive rapamycin i.t. injections on thermal and mechanical hypersensitivity in CGRP-Inp54p<sup>+/−</sup> (control) mice and Rosa-FRB<sup>PLF</sup>/CGRP-Inp54p compound heterozygous mice. After baseline testing, we injected these mice twice with rapamycin (i.t.) at 6 hour intervals, then injected CFA into one hindpaw immediately after the second injection. CFA injections were successful, as evidenced by edema (Figure 4D), thermal hypersensitivity (Figure 4E) and mechanical allodynia (Figure 4F) in the inflamed paw, but not the control paws. However, there were no significant differences between control and experimental groups, further suggesting that this two-component system was non-functional in DRG neurons.
Rapamycin treatment stabilized FRB<sup>PLF</sup>-CFP but did not induce translocation of Venus-FKB12-Inp54p in cultured DRG neurons

We next evaluated whether rapamycin could induce translocation of Venus-FKB12-Inp54p to the plasma membrane in cultured DRG neurons. To test this, we cultured DRG neurons from Rosa-FRB<sup>PLF</sup>/CGRP-Inp54p double heterozygous mice, treated cells for 10 min with vehicle or 1 μM rapamycin, then imaged both components (CFP and Venus fluorescence) using confocal microscopy. As with our in vivo studies above, rapamycin treatment did not induce translocation of Venus-FKB12-Inp54p to the plasma membrane (Figure 5). We then treated cultured DRG neurons from Rosa-FRB<sup>PLF</sup>/CGRP-Inp54p double heterozygous mice for longer periods of time. Unfortunately, we still were unable to detect translocation even after 24 hours (Figure 6A-B) or 48 hours (data not shown). Notably however, prolonged treatment with rapamycin stabilized FRB<sup>PLF</sup>-CFP, as evidenced by increased fluorescence signal after 24 hours (Figure 6A-B, quantified in Figure 6C; all gain settings the same). The FRB<sup>PLF</sup> domain can be stabilized within hours after dimerizing with endogenous FKB12 [25,37].

Our data suggested that DRG neurons might contain high levels of endogenous FKB12 that compete with Venus-FKB12-Inp54p for binding to FRB<sup>PLF</sup>-CFP. Moreover, we hypothesized that HEK293 cells might express lower levels of endogenous FKB12 than DRG neurons, given that Venus-FKB12-Inp54p did translocate to the membrane in HEK293 cells expressing FRB<sup>PLF</sup>-CFP (Figure 1). Indeed, we found that endogenous FKB12 levels were significantly higher in DRG when compared to HEK293 cells (Figure 7A-B). Although the level of FKB12 is only 1.5 higher in total DRG lysate (Figure 7B), this is likely an underestimation of FKB12 in DRG neurons due to dilution by non-neuronal DRG cells, as FKB12 is expressed more highly in neurons than non-neuronal surrounding cells of the DRG (Figure 7C-D). COS7 cells also contained low levels of FKB12 (data not shown), possibly explaining why Venus-FKB12-Inp54p translocated to the plasma membrane in this cell line as well (see above).
To delineate the localization of FKBP12, we immuno-
stained DRG sections from WT animals with antibodies
to FKBP12. FKBP12 was found throughout the cyto-
plasm in all neurons, and was often concentrated at the
membrane in large diameter DRG neurons (Figure 7C).
Notably, the satellite cells that surround DRG neurons
(marked by DRAQ5-positive nuclei) contained lower
levels of FKBP12 (Figure 7C). Likewise, in cultures of
dissociated DRG, high levels of FKBP12 were detected in
βIII Tubulin\textsuperscript{+} neurons (a neuronal-specific marker),
while βIII Tubulin\textsuperscript{−}, DRAQ5\textsuperscript{+} cells had lower levels of
FKBP12 (Figure 7D; quantified by image intensity ana-
lysis; p < 0.0001, data not shown). Thus, FKBP12 was
present at high levels in DRG neurons, and at low levels
in non-neuronal cells in the DRG.

Discussion
We successfully generated two knockin mice that each
expressed components of the rapamycin-inducible PIP\textsubscript{2}
depletion system. FRB\textsuperscript{PLF}-CFP and Venus-FKBP12
-Infp54p were expressed in the appropriate cell types and
each of these proteins was targeted to the correct sub-
cellular location (membrane and cytoplasm, respect-
ively). While Venus-FKBP12-Infp54p translocated to the
membrane in cell lines expressing FRB\textsuperscript{PLF}-CFP, we were
unable to detect rapamycin-induced translocation of
these components in DRG neurons in vitro or in vivo.
Furthermore, rapamycin treatment of double heterozy-
gous mice did not alter thermal sensitivity as we would
have expected if the system had worked in vivo. While
this chemically-induced translocation tool is widely used
for manipulation in cell lines, our data collectively sug-
gest that high levels of endogenous FKBP12 limit its
functionality in DRG neurons (Figure 8).

While rapamycin did not induce translocation in DRG
neurons, it did enhance CFP-FRB\textsuperscript{PLF} protein fluores-
cence intensity, suggesting that rapamycin interacted
with FRB\textsuperscript{PLF} and promoted dimerization to endogenous
FKBP12. The FRB domain mutation used in our Rosa-
FRB mouse consists of three point mutations: K2095P,
T2098L, and W2101F [26]. These mutations allow for
the use of rapamycin analogs that do not cross-react
with the wildtype, endogenous FRB domain of mTOR.
One of these mutations (T2098L) is responsible for pro-
tein destabilization, and this destabilized FRB mutant
has been previously used for successful dimerization
in vivo [25,26,37]. Interestingly, this destabilization is
extended to proteins fused to the FRB\textsuperscript{PLF} mutant, such as
fluorescent tags, and is reversed upon FKBP12-
rapamycin-FRB\textsuperscript{PLF} complex formation, with a half-
maximal result approximately 8 hours after rapamycin treatment [25,37]. The fact that FRB$^{PLF}$-CFP protein levels were increased demonstrates that rapamycin was in fact reaching its intended target in DRG neurons. However, Venus-FKBP12-Inp54p failed to translocate, suggesting that endogenous FKBP12 could be responsible for this stabilization. Indeed, DRG neurons contain higher levels of endogenous FKBP12 than HEK293 cells (Figure 7). Endogenous FKBP12 in DRG neurons could potentially out-compete Venus-FKBP12-Inp54p for binding to FRB$^{PLF}$, and thus prevent Venus-FKBP12-Inp54p from translocating to the membrane. Alternatively, the levels of mTOR, the protein that contains the endogenous FRB domain, could have a similar effect on sequestering the transgenic Venus-FKBP12-Inp54p protein away from the membrane-tagged FRB$^{PLF}$ domain.

Figure 5 Short-term rapamycin treatment does not induce translocation of Venus-FKBP12-Inp54p in cultured DRG neurons. A) Cultured DRG neurons from male Rosa-FRB$^{PLF}$/CGRP-Inp54p mice were plated for 24 hours. B) 1 μM rapamycin was applied for 10 minutes, and post-rapamycin images were taken. C) Close-up (5x zoom) of box region in (A) to show pre-rapamycin localization, and D) 5x zoom of box region in (B) to demonstrate the lack of Inp54p enrichment to FRB-tagged membrane after rapamycin treatment. A-D show FRB$^{PLF}$-CFP localization, A'-D' demonstrate Venus-FKBP12-Inp54p localization, and the merge is shown in A''-D''.
The rapamycin analog C20-Marap binds to FRB$^{PLF}$ without interacting with endogenous mTOR [26]; therefore, this compound could potentially be used to rule out the role of endogenous mTOR as a source of translocation inhibition. However, it should be emphasized that use of rapalogs would not overcome the problem we identified, namely interaction of FRB with endogenous FKBP12. Overexpression of Inp54p in cell lines can lead to loss of cell adhesion, induction of membrane blebbing, and ultimately cell death [38,39]. Expression after

Figure 6 Rapamycin stabilizes FRB$^{PLF}$-CFP in cultured DRG neurons but does not induce translocation of Venus-FKB12-Inp54p. A) Confocal images of cultured DRG neurons from Rosa-FRB$^{PLF}$/CGRP-Inp54p double heterozygous mice after culturing for 24 hours in presence of vehicle or 1 μM rapamycin. B) Quantification following vehicle/rapamycin treatment. While the ratio of FRB$^{PLF}$-CFP increases after rapamycin treatment, this is due to C) an increase in FRB$^{PLF}$-CFP fluorescence, rather than translocation. n = 86 neurons per condition ***P < 0.0001. Scale bar, 20 μm.
Figure 7 Endogenous FKBP12 protein levels are significantly higher in DRG neurons when compared to HEK293 cells. A) Western blot of HEK293 cell lysates (from 4 separate cultures) and DRG lysates (dissected from three 8-week old WT mice) probed with antibodies to FKBP12 and beta-actin. B) Quantification of the FKBP12 protein levels, normalized to actin loading control. ***p < 0.0001. C) Section from WT DRG immunostained with antibodies to FKBP12 and counterstained with DRAQ5 to mark nuclei. Scale bar, 20 μm. D) Dissociated neurons stained with anti-βIII Tubulin (a neuron-specific marker), anti-FKBP12, and DRAQ5. Endogenous FKBP12 is present at much higher levels in neurons compared to non-neuronal cells (tubulin+, DRAQ5− cells; p < 0.0001). Scale bar, 10 μm.

Figure 8 Model: endogenous FKBP12 limits use of rapamycin-induced translocation in DRG neurons but not HEK293 cells. A) In HEK293 cells, rapamycin promotes dimerization of membrane-tethered FRB\textsubscript{PLF}-CFP with Venus-FKBP12-Inp54p. Once at the membrane, Venus-FKBP12-Inp54p hydrolyzes PIP\textsubscript{2} to PI(4)P. B) DRG neurons contain high levels of endogenous FKBP12 in the cytoplasm and, in some neurons, on the membrane. Rapamycin stabilizes FRB\textsubscript{PLF}-CFP (bold), but does not promote translocation of Venus-FKBP12-Inp54p to the membrane. These data suggest that rapamycin preferentially facilitates dimerization of FRB\textsubscript{PLF}-CFP with endogenous FKBP12 and occludes dimerization with Venus-FKBP12-Inp54p. Venus-FKBP12-Inp54p remains in the cytoplasm, unable to access PIP\textsubscript{2} in the membrane.
transfection in cultured cells tends to be on the timescale of a few days, whereas these mice express Venus-FKBP12-Inp54p throughout the life of the animal. It is possible that some compensation occurs when Inp54p is expressed over longer time scales.

In addition to elevated levels of endogenous FKBP12, other factors might limit rapamycin-induced translocation in vivo. Based on our experiments with FRB<sup>PLF</sup>, FKBP12-Inp54p, and PH constructs in cell lines, we noticed that the ratio between the three proteins varied highly between individual cells. Indeed, others similarly noted that the ratio of each component was critical for experimental success [29,40]. Therefore, the ratio of FRB<sup>PLF</sup>-CFP to Venus-FKBP12-Inp54p in our mice might be suboptimal for translocation.

Given the widespread use of rapamycin-induced dimerization to study biological processes in cell lines, it is perhaps remarkable to note that there is only one publication describing the use of rapamycin-induced heterodimerization in vivo [25]. Notably, in this study Stankunas et al. use rapamycin analogs to dimerize and stabilize a cytoplasmically localized FRB<sup>PLF</sup> fusion protein with endogenous FKBP12 (also cytoplasmic) in cultured mouse embryonic fibroblasts (MEFs) and embryonic forelimb tissue. They did not attempt to dimerize FRB<sup>PLF</sup> with an engineered FKBP-domain to translocate protein, nor did their study utilize this system in neurons. Karpova and colleagues used a FKBP homodimerization system, consisting of two mutated FKBP domains (F36V) to regulate neurotransmission in transgenic mice [41]. Thus, it appears that no lab has successfully found a way to inducibly heterodimerize engineered FRB with engineered FKBP in vivo.

Conclusions
While rapamycin-induced translocation is highly effective for studying signaling events in a temporally-controlled manner in cell lines, our results—taken together with the lack of published reports of rapamycin-induced translocation in vivo—suggest that there are limitations that prevent the adaptation of this system for use in neurons in vitro and in vivo. Supporting this hypothesis, we found that brain lysates and DRG lysates had equally high levels of FKBP12, and it has previously been noted that high levels of FKBP12 mRNA are found throughout nervous tissue, including cerebral cortex and hippocampus, compared to non-neuronal tissue [42]. Therefore, elevated levels of endogenous FKBP12 could restrict the utilization of rapamycin-induced translocation in neuronal cells in general. To our knowledge, this issue has not been previously identified or raised. Our study could thus spur the development of new reagents, like novel rapalogs that interact with engineered versions of FKBP12 but not endogenous FKBP12. Such reagents, when combined with FRB mutants that do not interact with endogenous mTOR, could allow greater adoption of this dimerization system in vitro and in vivo.

Methods
All procedures and behavioral experiments involving vertebrate animals were approved by the Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill.

DNA plasmid constructs
Constructs for rapamycin-induced PIP<sub>2</sub> depletion in HEK293 cells were obtained from Ken Mackie (University of Indiana), Tamas Balla (NICHD, Bethesda, MD USA) and Tobias Meyer (Stanford, Stanford, CA USA). The RFP-tagged PH domain of rat PLCδ1 was a kind gift from Ken Mackie. The CFP-tagged FRB domain was tethered to the plasma membrane using the first 20 amino acids of the human GAP43, as described in Vánai et al. (2006), was obtained from Tamas Balla, and cloned into pcDNA3.1(+). The FKBP-Inp54p yeast 5-phosphatase construct was a gift from Tobias Meyer, cloned into pcDNA3.1(+), and modified with a Venus fluorescent protein tag.

Cell culture and live-imaging
HEK293 cells were grown on glass bottom cell culture dishes (MatTek; P35G-0-10-C) in Dulbecco’s Modified Eagle Medium (DMEM, Sigma) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. Cells were transfected with 4 μl Lipofectamine 2000 (Invitrogen) and 1 μg total DNA per culture dish in Opti-MEM (Gibco) for 2 hours, at which point media was replaced with the supplemented DMEM. After 16–24 hours, supplemented DMEM was replaced with Hank’s Balanced Salt Solution (HBSS Gibco 14025, supplemented with 9 mM HEPES, 11 mM D-glucose, 0.1% fatty-acid free BSA, pH 7.3) warmed to 37°C. After baseline imaging, HBSS was replaced with HBSS containing 1 μM rapamycin (Calbiochem). Each plate was imaged on a Leica TCS confocal microscope using a 40x objective, and maintained at 37°C throughout the imaging session using a heated stage attachment. Cells were treated for 10 minutes, at which point a final post-rapamycin image was taken. Membrane to cytoplasm ratio in pre- and post-rapamycin-treated cells was measured in cells expressing all three constructs, using NIH ImageJ software.

Generation of FRB<sup>PLF</sup>-CFP and Venus-FKBP12-Inp54p knockin mice
The GAP43-FRB<sup>PLF</sup>-CFP construct containing three point mutations of the FRB domain (K2095P, T2098L, and W2101F) was cloned into the Rosa26 targeting
with PBS to remove fixative, mounted on slides, and imaged on a Leica TCS confocal microscope. CFP was excited with a 458 nm laser and detected with emission settings of 465–505 nm, and Venus was excited using a 514 nm laser and detected with emission settings of 528–587 nm.

**Immunohistochemistry**

For DRG tissue sections, male mice 4–6 weeks were injected intraperitoneally with pentobarbital, and perfused with 4% PFA in 0.1 M phosphate buffer, pH 7.4. Lumbar DRG (L2-L6) were dissected and post-fixed for 2 hours in 4% PFA. The DRG were subsequently cryoprotected in 30% sucrose, 0.1 M phosphate buffer, pH 7.3 at 4°C for 24 h, frozen in OCT TissueTek, cryosectioned at 20 μm, mounted on Superfrost Plus slides, and stored at −20°C until use. Tissue was rehydrated and washed in PBS to remove OCT embedding compound, and either coverslipped immediately, or prepared for immunohistochemistry (IHC). DRG sections and dissociated neurons were permeabilized and blocked in TBS-Tx (0.05 M Tris, 2.7% NaCl, 0.3% Triton-X 100, pH 7.6) containing 10% normal goat serum (NGS) for 1 hr at room temperature. Sections were incubated overnight at 4°C with primary antibodies in TBS-Tx/10%NGS, washed, incubated at room temperature for 2 hours with secondary antibodies in TBS-Tx/10%NGS, washed, and mounted with Fluorogel (Biomedia). Primary antibodies used were chicken anti-GFP (1:500; Aves Labs, GFP-1020), rabbit anti-CGRP (1:750; Peninsula, T-4032), mouse anti-NeuN (1:200, Millipore), and rabbit anti-FKBPL2 (1:125, Abcam) in TBS-Tx/10% NGS. Secondary antibodies include goat anti-chicken Alexa fluor 488 (1:2000, Invitrogen), goat anti-Rabbit Alexa flour 633 (1:2000, Invitrogen), goat anti-mouse Alexa flour 633 (1:2000, Invitrogen), Alexa flour 633 conjugated to IB4 (1:1000, Invitrogen), and DRAQ5 (1:10000, Axxora).

**Biochemistry**

Cells were lysed in ice-cold RIPA buffer: Tris, pH 7.4 (50 mM), Triton-X (1%), Sodium Dextocholate (0.25%), SDS (0.1%), EDTA (1 mM), NaCl (150 mM), Complete Protease Inhibitory Cocktail (1x, Roche), PMSF (1 mM). HEK293 cells were scraped from a 10 cm dish in RIPA buffer, and DRG were homogenized in RIPA buffer prior to spindown. Lysates were placed on ice for 20 minutes, then spun at 13200 rpm for 10 minutes. Supernatant was removed and used for Western blot analysis. Twenty micrograms of protein were loaded per lane in a 4–15% Tris gel, transferred onto PVDF membrane, blocked with 5% milk in TBS-T, incubated with primary antibodies (rabbit anti-FKBPL2, Abcam, 1:1000; mouse anti-actin 1:3000) in 3% milk in TBS-T at 4°C overnight,
washed in TBS-T, incubated with secondary antibodies (donkey anti-rabbit 800, Odyssey, 1:20000; donkey antimouse 680, Odyssey, 1:20000) for 1 hour at room temperature, washed, and developed.

Drug administration for tissue extraction
Mice that were heterozygous for CGRP-Inp54p, or heterozygous for both Rosa-FRBPLF and CGRP-Inp54p, received three intrathecal injections (each containing 1 nmol rapamycin, dissolved in saline to a total volume of 5 μL) over the course of 24 hours. Mice were then perfused and dissected, as described above, two hours after the second round of injections.

Behavior
Male 3- to 4-month-old CGRP-Inp54p+/− and WT littermates (n = 12 per genotype), or Rosa-FRBPLF/CGRP-Inp54p and CGRP-Inp54p heterozygous littermates (n = 10 per genotype), were acclimated to the testing apparatuses and experimenter for 2 days prior to behavioral testing. The experimenter was blind to genotype throughout the experiment. For CGRP-Inp54p+/− and WT controls, baseline thermal and mechanical responses were monitored using Hargreaves and Von Frey apparatuses (as previously described in [22]) prior to intraplantar injection with complete Freund’s adjuvant (CFA) into the left hindpaw. Behavior testing for both thermal and mechanical sensitization was carried out on subsequent days, as described previously [22]. Rosa-FRBPLF/CGRP-Inp54p double heterozygous and CGRP-Inp54p+/− littermate controls were used to determine the extent of rapamycin-induced depletion of PIP2 in the reduction of pain sensitivity in vivo. For this, each mouse received two intrathecal injections of rapamycin (1 nmol in 5 μL), one just after baseline measurement, and one just prior to CFA injection into the hindpaw 6 hours later, and behavioral testing was carried out on subsequent days.

Competing interests
The authors declare that they have no competing interests in this study.

Authors’ contributions
JCB, SBS, and MJZ conceived of and designed the experiments used in this study, JCB and BIF carried out the experiments presented in this manuscript, while SBS and JER performed experiments leading to the findings described in this manuscript. JCB and MJZ wrote the manuscript, and all authors approved the submission of this work.

Acknowledgements
The authors would like to acknowledge Ken Mackie, Tamas Balla, and Tobias Meyer for providing constructs, JiGang Cheng from the University of North Carolina (UNC) BAC Core for generating the CGRP knockin targeting arms, the UNC Animal Models Core for generating chimeras, Brittany Wright for technical assistance and scientific discussion, and members of the Zylka lab for comments on the manuscript. This work was supported by 1F31NS068038 (to JCB), P30NS045892 (BAC Core funding), and an anonymous donor (to MJZ).

References
1. Crabtree GR, Schreiber SL: Three-pair inventions: intracellular signaling and induced proximity. Trends Biochem Sci 1996, 21:418–422.
2. Jin L, Zeng H, Chien S, Otto K, Richard RE, Emery DW, Biau A: In vivo selection using a cell-growth switch. Nature Genet 2000, 26:64–66.
3. Suh B-C, Inoue T, Meyer T, Hille B: Rapid chemically induced changes of PtdIns(4,5)P2 gate KCNQ ion channels. Science 2006, 314:1454–1457.
4. Varnai P, Thyagarajan B, Rohacs T, Balla T: Rapidly inducible changes in phosphatidylinositol 4,5-bisphosphate levels influence multiple regulatory functions of the lipid in intact living cells. J Cell Biol 2006, 175:377–382.
5. Xu T, Johnson CA, Gestwicki JE, Kumar A: Conditionally controlling nuclear trafficking in yeast by chemical-induced protein dimerization. Nat Protocol 2010, 5:1831–1843.
6. Putnyki M, Schultz C: Switching Heterotrimeric G Protein Subunits with a Chemical Dimmerizer. Chem Biol 2011, 18:126–133.
7. Majerus PW, Ross TS, Cunningham TW, Caldwell KK, Jefferson AB, Bansai VS: Recent insights in phosphatidylinositol signaling. Cell 1990, 63:459–465.
8. Suh B-C, Hille B: PIP2 is a necessary cofactor for ion channel function: how and why? Annu Rev Biophys 2008, 37:175–195.
9. McLaughlin S, Wang J, Gambhir A, Murray D: PIP2(2) and proteins; interactions, organization, and information flow. Annu Rev Biophys Biomol Struct 2002, 31:151–175.
10. Szentpetery Z, Balla A, Kim Y, Lemmon M, Balla T: Live cell imaging with protein domains capable of recognizing phosphatidylinositol 4,5-bisphosphate; a comparative study. BMC Cell Biol 2009, 10:67.
11. Varnai P, Balla T: Visualization of Phosphoinositides That Bind Pleckstrin Homology Domains: Calcium- and Agonist-induced Dynamic Changes and Relationship to Myo-[3H]inositol-labeled Phosphoinositide Pools. J Cell Biol 1998, 143:501–510.
12. Stauffer T, Ahn S, Meyer T: Receptor-induced transient reduction in plasma membrane PtdIns(4,5)P2 concentration monitored in living cells. Curr Biol 1998, 8:343–346.
13. Gamper N, Shapiro M: Regulation of ion transport proteins by membrane phosphoinositides. Nat Rev Neurosci 2007, 8:491–494.
14. Zaika O, Zhang J, Shapiro M: Visualization of phosphoinositides that bind pleckstrin homology domains. J Cell Biol 2001, 151:129–140.
15. Reid A, O’Driscoll A, Nally T, Hynes O: Rapamycin induced depletion of PIP2 and Ca2+ signals mediating receptor specificity toward neuronal Ca2+ channels. J Biol Chem 2011, 286:15187–15197.
16. Varnai P, Israel R, Balla T: Visualization of Phosphoinositides That Bind Pleckstrin Homology Domains: Calcium- and Agonist-induced Dynamic Changes and Relationship to Myo-[3H]inositol-labeled Phosphoinositide Pools. J Cell Biol 1998, 143:501–510.
17. Halpain S, Comoglio P: Phosphoinositides: from biochemistry to signaling. Curr Opin Cell Biol 2003, 15:611–617.
18. Ikeda S, Ikeda T, Sato Y, Nishizawa M, Sekine S, Komatsu S, Tsurumi K: Rapamycin selectively inhibits class IA phosphatidylinositol 3-kinase in mouse embryonic fibroblasts. J Biol Chem 1998, 273:30203–30208.
19. Kim A, Tang Z, Lu Q, Patel K, Maag D, Geng Y, Dong X: Dual regulation of TRPV1 channels. Cell 2008, 133:475–485.
20. Klein RM, Ufflet-Ventury CA, Hua L, Gordon SE: Determinants of molecular specificity in phosphoinositide regulation. Phosphatidylinositol (4,5)-bisphosphate (P1(4,5)P2) is the endogenous lipid regulating TRPV1. J Biol Chem 2008, 283:26028–26036.
21. Daniels R, Takahira Y, McKenny D: Activity of the neuronal cold sensor TRPβ8 is regulated by phosphoinositide-binding protein, functions as a regulatory subunit of TRPV1. Cell 2008, 133:475–485.
22. Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate. J Neurosci 2010, 30:10262–10293.
23. McCoy E, Taylor-Blake B, Zylka M: CGRPα-expressing sensory neurons respond to stimuli that evoke sensations of pain and itch. PLoS One 2012, 7:e36355.
24. McCoy ES, Taylor-Blake B, Street SE, Pržibiski ÁL, Zheng J, Zylka MJ: Peptidergic CGRPα Primary Sensory Neurons Encode Heat and Itch and Tonically Suppress Sensitivity to Cold. Neuron 2013, 78:136–151.
25. Stankunas K, Bayle JH, Gestwicki JE, Lin YM, Wandless TJ, Crabtree GR: Conditional protein alleles using knockin mice and a chemical inducer of dimerization. Mol Cell 2003, 12:1615–1624.

26. Bayle J, Grimes J, Stankunas K, Gestwicki J, Wandless T, Crabtree G: Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem Biol 2006, 13:99–107.

27. Schmidt-Michels M, Edwards P, Gestricher A, Gispel W: Colchicine effect on B-50/GAP43 phosphoprotein localization in rat dorsal root ganglion explants. Neurosci Lett 1989, 97:285–290.

28. Graham F, Smiley J, Russell W, Naim R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36:69–74.

29. Balla T, Várnai P: Visualizing cellular phosphoinositide pools with GFP-fused protein modules. Sci STKE 2002, 125pl3.

30. Zylka M, Sowa N, Taylor-Blake B, Twomey M, Herrala A, Voikar V, Vihko P: Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 2008, 60:111–122.

31. Cavanaugh DJ, Lee H, Lo L, Shields SD, Zylka MJ, Basbaum AI, Anderson DJ: A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. Nat Neurosci 2009, 12:151–175.

32. Soriano P: Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999, 21:70–71.

33. Stirling LC, Forlani G, Baker MD, Wood JN, Matthews EA, Dickenson AH: Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem Biol 2006, 13:99–107.

34. Balla T, Varnai P: Visualizing cellular phosphoinositide pools with GFP-fused protein modules. Sci STKE 2002, 125pl3.

35. Zylka M, Sowa N, Taylor-Blake B, Twomey M, Herrala A, Voikar V, Vihko P: Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 2008, 60:111–122.

36. Graham F, Smiley J, Russell W, Naim R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36:69–74.

37. Azuma T, Koths K, Flanagan L, Kwiatkowski D: Decreased nociceptive sensitization in mice lacking the fragile X mental retardation protein: Role of mGlur1/5 and mTOR. J Neurosci 2003, 23:9703–9711.

38. Azuma T, Koths K, Flanagan L, Kwiatkowski D: Gelsolin in Complex with Phosphatidylinositol 4,5-Bisphosphate Inhibits Caspase-3 and to 9t o Retard Apoptotic Progression. J Biol Chem 2000, 275:3761–3766.

39. Raucher D, Stauffer T, Chen W, Shen K, Guo S, et al: Phosphatidylinositol 4,5-bisphosphate functions as a second messenger that regulates cytoskeleton-plasma membrane adhesion. Cell 2003, 100:221–228.

40. Komatsu T, Kukelyansky I, McCaffery JM, Ueno T, Varela LC, Inoue T: Distinct subsets of unmyelinated primary sensory fibers mediate behavioral responses to noxious thermal and mechanical stimuli. Neuron 2009, 60:151–175.

41. Komatsu T, Kukelyansky I, McCaffery JM, Ueno T, Varela LC, Inoue T: Distinct subsets of unmyelinated primary sensory fibers mediate behavioral responses to noxious thermal and mechanical stimuli. Neuron 2009, 60:151–175.

42. Su A, Wiltshire T, Batalov S, Lapp H, Ching K, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, et al: A gene atlas of the mouse and human protein-encoding transcripts. Proc Natl Acad Sci USA 2004, 101:6062–6067.

43. Bunting M, Bernstein K, Greer J, Capecci M, Thomas K: Targeting genes for self-excision in the germ line. Genes & Dev 1999, 13:1524–1528.